吉林大学学报(医学版) ›› 2013, Vol. 39 ›› Issue (1): 152-155.doi: 10.7694/jldxyxb20130134

• 临床医学 • 上一篇    下一篇

复方二氯醋酸二异丙胺对他莫昔芬所致脂肪性肝病的治疗作用

孙 艳1，赵怡璇2，李亚荣1，夏大文1，迟宝荣3   

  1. 1.吉林大学第二医院肿瘤?血液内科， 吉林 长春 130041；2.吉林大学第二医院电诊
    科，吉林 长春 130041；3.吉林大学第一医院消化内科， 吉林 长春 130021
  • 收稿日期:2012-09-27 出版日期:2013-01-28 发布日期:2013-01-30
  • 通讯作者: 迟宝荣 （Tel: 0431-88782528；E-mail:chibr@jlu.edu.cn） E-mail:chibr@jlu.edu.cn
  • 作者简介:孙 艳（1976-），女，河南省许昌市人，主治医师，医学博士，主要从事肿瘤及血液疾病基础和临床研究。 
  • 基金资助:

     吉林省科技厅科研基金资助课题（20120953）

Curative effects of compound diisopropylamine dichloroacetate injection on fatty liver disease induced by tamoxifen


SUN Yan1,ZHAO Yi-xuan2,LI Ya-rong1,XIA Da-wen1,CHI Bao-rong3   

  1. 1.Department of Oncology and Hematology,Second Hospital,Jilin University,Changchun 130041,China；2. Department of Ultrasonic Diagnosis，Second Hospital,Jilin University,Changchun 130041,China；3.Department of Gastroenterology,First Hospital,Jilin University,Changchun 130021,China
  • Received:2012-09-27 Online:2013-01-28 Published:2013-01-30

PDF (PC)

338

赞

摘要： 目的：观察复方二氯醋酸二异丙胺（CDDI）治疗他莫昔芬（TAM）所致脂肪性肝病的临床疗效，为其临床应用提供理论依据。方法：应用TAM治疗后出现脂肪性肝病的乳腺癌患者72例，随机分为对照组（38例）和治疗组（34例）。对照组患者行基础治疗，治疗组患者除基础治疗外，给予CDDI 80 mg?d-1静点，疗程4周。观察各组患者治疗前后临床症状、肝功能酶学、血脂、肝脏影像学变化及用药期间不良反应。结果：治疗后治疗组总有效率82.3%
,对照组总有效率23.7%,2组比较差异有统计学意义（P<0.01）。与治疗前比较，治疗后治疗组患者血清丙氨酸氨基转移酶(ALT)、总胆固醇(TC)及甘油三酯(TG)水平均有明显下降，差异有统计学意义（P<0.05），与对照组治疗后比较差异也有统计学意义（P<0.05）；对照组患者治疗后上述指标虽有轻度变化，但与治疗前比较差异无统计学意义（P>0.05）。治疗期间2组患者均未见明显不良反应。结论：CDDI对TAM所致脂肪性肝病具有较好的临床疗效。

关键词:  , 二氯乙酸盐/ 治疗应用, 丙胺类/ 治疗应用, 他莫昔芬, 脂肪性肝病

Abstract: Objective To observe the clinical curative effects of compound diisopropylamine dichloroacetate (CDDI) in treating fatty liver disease induced by ta
moxifen(TAM) and to provide theoretical basis for its clinical application.Methods 72 cases of breast cancer patients with fatty liver disease induced by TAM were randomly divided into control group(n=38) and treatment group(n=34).The patients in control group were treated with   basic treatment alone.The patients in treatment group were injected intravenously  with CDDI 80 mg  once daily for 4 weeks in addition to basic treatment.The changes of clinical symptoms,liver function enzymes,blood lipids and liver imaging   of the patients in two groups were observed before and after treatment.The efficacy and safety of drugs were examined.Results After treatment，the total effective rates were 82.3% in treatment group and 23.7% in cont
rol group,there was significantly difference between two groups（P<0.01）.Compared with before treatment,the contents of alanine aminotransferase (ALT),total cholesterol (TC),and triglyceride (TG)of the patients in treatment group were significantly decreased after treatment（P<0.05）;and there also were  significant differences compared with control group after treatment(P<0.05).There were no significant differences of the
 contents of ALT,TC and TG in control group between before treatment and after treatment（P>0.05）.No severe adverse drug reactions were found in two groups during treatment period.Conclusion  CDDI could be used as a effective drug in the treatment of fatty liver disease induced by TAM.

Key words: diisoprorylamine/therapeutic use, dichloroacetate/therapeutic use, tamoxifen, fatty liver diseases

中图分类号: 

  •  
网站版权 © 《吉林大学学报(医学版)》编辑部
地址：长春市新民大街828号(130021)　电话：+86-431-85619279　E-mail: xuebao@jlu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发